$0.00
0.00%
Nasdaq, Sep 28, 09:30 am EDT.
ISIN
US65344D1090
Symbol
NEXI

Neximmune Inc Stock price

$0.00
+0.00 0.00% 1M
-0.00 66.67% 6M
+0.00 0.00% YTD
-0.00 50.00% 1Y
-5.12 100.00% 3Y
-418.75 100.00% 5Y
-425.00 100.00% 10Y
-425.00 100.00% 20Y
Nasdaq, Closing price Mon, Sep 28 2026
+0.00 0.00%
ISIN
US65344D1090
Symbol
NEXI
Industry

Is Neximmune Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$0.0
Enterprise Value
$-2.4m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
0.0
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.0
Financial Health
Equity Ratio
40.8%
Return on Equity
-
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
1.3%
Employees
6
Rev per Employee
-

Neximmune Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Neximmune Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Neximmune Inc forecast:

Buy
86%
Hold
14%

Financial data from Neximmune Inc

Jun '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
25% 25%
-
- Research and Development Expense 9.67 9.67
73% 73%
-
-19 -19
60% 60%
-
- Depreciation and Amortization 0.69 0.69
34% 34%
-
EBIT (Operating Income) EBIT -20 -20
59% 59%
-
Net Profit -21 -21
58% 58%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neximmune Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neximmune Inc Stock News

Positive
Reuters
●
4 months ago
Italian state investor CDP Equity plans to raise its stake ​in payments group Nexi to as much ‌as 29.9%, it said on Monday, bolstering a player in a sector viewed as increasingly strategic.
Positive
Reuters
●
5 months ago
Italy's state lender Cassa ​Depositi e Prestiti (CDP) has ‌no plans to divest from payments group Nexi NEXII.Mi, two sources familiar with ​the matter said on ​Wednesday.

Company Profile

NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke in June 7, 2011 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Mr. Jalbert
Employees 6
Founded 2011
Website www.neximmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today